Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer.
Clemens P SpielvogelStefan StoiberLaszlo PappDenis KrajncMarko GrahovacElisabeth GurnhoferKarolina TrachtovaVojtech BystryAsha LeisserBernhard JankJulia SchnoellLorenz KadletzGregor HeiduschkaThomas BeyerMarcus HackerLukas KennerAlexander R HaugPublished in: European journal of nuclear medicine and molecular imaging (2022)
Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies.